A Derived Neutrophil to Lymphocyte Ratio Predicts Survival in Patients with Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2012 Jul 26

PMID 22828611

Citations 239

Authors

M J Proctor

D C McMillan

D S Morrison

C D Fletcher

P G Horgan

S J Clarke

Affiliations

Soon will be listed here.

Abstract

Background: The neutrophil lymphocyte ratio (NLR) has prognostic value in patients with a variety of cancers. Many chemotherapeutic trial databases hold information on white cell and neutrophil counts only. The aim of the present study was to compare the prognostic value of the NLR with a derived score (dNLR), composed of white cell and neutrophil counts.

Methods: Patients (n=27,031) who were sampled incidentally between 2000 and 2007 for neutrophil, lymphocyte and white cell counts, and also had a diagnosis of cancer (Scottish Cancer Registry), were identified. Of this group, 12,118 patients who had been sampled within 2 years of their cancer diagnosis were studied.

Results: On follow-up, there were 7366 deaths, of which 6198 (84%) were cancer deaths. The median time from blood sampling to diagnosis was 2.1 months. The area under the receiver-operating characteristic (ROC) curve for cancer-specific survival was 0.650 for the NLR and 0.640 for the dNLR. The NLR and dNLR were independently associated with survival in all cancers studied (all P<0.001). The optimal thresholds, on the basis of hazard ratios and area under the curve, were 4 : 1 for the NLR and 2 : 1 for the dNLR.

Conclusion: The results of the present study show that the dNLR has similar prognostic value to the NLR. Therefore, the universally available dNLR is to be commended for use in the risk stratification of patients undergoing chemotherapy.

Citing Articles

Baseline (derived) neutrophil-lymphocyte ratio associated with survival in gastroesophageal junction or gastric cancer treated with ICIs.

Yu C, Jiang H, Wang L, Jiang Z, Jin C Front Oncol. 2025; 15:1404695.

PMID: 39926278 PMC: 11802431. DOI: 10.3389/fonc.2025.1404695.

Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.

Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K Cancer Med. 2025; 14(2):e70618.

PMID: 39840727 PMC: 11751879. DOI: 10.1002/cam4.70618.

Neutrophil diversity and function in health and disease.

Zhang F, Xia Y, Su J, Quan F, Zhou H, Li Q Signal Transduct Target Ther. 2024; 9(1):343.

PMID: 39638788 PMC: 11627463. DOI: 10.1038/s41392-024-02049-y.

Prognostic impact of osteosarcopenia on postoperative outcomes in patients with biliary tract cancer.

Shimagaki T, Sugimachi K, Tomino T, Onishi E, Koga N, Kasagi Y Surg Today. 2024; .

PMID: 39625483 DOI: 10.1007/s00595-024-02972-1.

The Role of Lymphocytic Infiltrates in the Tumor Microenvironment as a Predictive Factor for the Response to Immunotherapy in Solid Tumors: A Single-Center Experience From Romania.

Mihaila R, Gheorghe A, Zob D, Stanculeanu D Cureus. 2024; 16(11):e74194.

PMID: 39583615 PMC: 11582497. DOI: 10.7759/cureus.74194.

References

Kao S, Pavlakis N, Harvie R, Vardy J, Boyer M, van Zandwijk N . High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010; 16(23):5805-13. DOI: 10.1158/1078-0432.CCR-10-2245. View

Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M . Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol. 2010; 184(3):873-8. DOI: 10.1016/j.juro.2010.05.028. View

Halazun K, Aldoori A, Malik H, Al-Mukhtar A, Prasad K, Toogood G . Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2007; 34(1):55-60. DOI: 10.1016/j.ejso.2007.02.014. View

Fidler I, Poste G . The "seed and soil" hypothesis revisited. Lancet Oncol. 2008; 9(8):808. DOI: 10.1016/S1470-2045(08)70201-8. View

Kim H, Han K, Chung H, Kim J, Park N, Song Y . Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: a case-matched comparison. Eur J Surg Oncol. 2010; 36(7):691-8. DOI: 10.1016/j.ejso.2010.05.004. View

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A . Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009; 30(7):1073-81. DOI: 10.1093/carcin/bgp127. View

Sharaiha R, Halazun K, Mirza F, Port J, Lee P, Neugut A . Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011; 18(12):3362-9. PMC: 3192937. DOI: 10.1245/s10434-011-1754-8. View

Azab B, Bhatt V, Phookan J, Murukutla S, Kohn N, Terjanian T . Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2011; 19(1):217-24. DOI: 10.1245/s10434-011-1814-0. View

Chua W, Charles K, Baracos V, Clarke S . Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011; 104(8):1288-95. PMC: 3078587. DOI: 10.1038/bjc.2011.100. View

10.

Proctor M, Talwar D, Balmar S, OReilly D, Foulis A, Horgan P . The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer. 2010; 103(6):870-6. PMC: 2966631. DOI: 10.1038/sj.bjc.6605855. View

11.

Walsh S, Cook E, Goulder F, Justin T, Keeling N . Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005; 91(3):181-4. DOI: 10.1002/jso.20329. View

12.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

13.

Leitch E, Chakrabarti M, Crozier J, McKee R, Anderson J, Horgan P . Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007; 97(9):1266-70. PMC: 2360467. DOI: 10.1038/sj.bjc.6604027. View

14.

Proctor M, Morrison D, Talwar D, Balmer S, OReilly D, Foulis A . An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011; 104(4):726-34. PMC: 3049591. DOI: 10.1038/sj.bjc.6606087. View

15.

Cho H, Hur H, Kim S, Kim S, Kim J, Kim Y . Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2008; 58(1):15-23. PMC: 11029845. DOI: 10.1007/s00262-008-0516-3. View

16.

Gomez D, Morris-Stiff G, Toogood G, Lodge J, Prasad K . Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol. 2008; 97(6):513-8. DOI: 10.1002/jso.21001. View

17.

Lee Y, Choi C, Sung C, Do I, Huh S, Song T . Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol. 2011; 124(1):92-7. DOI: 10.1016/j.ygyno.2011.09.034. View

18.

Sarraf K, Belcher E, Raevsky E, Nicholson A, Goldstraw P, Lim E . Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009; 137(2):425-8. DOI: 10.1016/j.jtcvs.2008.05.046. View

19.

Ding P, An X, Zhang R, Fang Y, Li L, Chen G . Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis. 2010; 25(12):1427-33. DOI: 10.1007/s00384-010-1052-0. View

20.

Proctor M, Morrison D, Talwar D, Balmer S, Fletcher C, OReilly D . A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011; 47(17):2633-41. DOI: 10.1016/j.ejca.2011.03.028. View